-
Tianyao: Methylprednisolone sodium succinate for injection passed the consistency evaluation
Time of Update: 2021-06-06
Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection obtained drug registration approval issued by the National Medical Products Administration in November 2012.
In March 2019, Jinyao Pharmaceutical submitted a supplementary application for consistency evaluation to the Drug Evaluation Center of the National Medical Products Administration and was accepted.
-
How does Merck do well in China's pharmaceutical process behind the production of Taibang biological blood products...
Time of Update: 2021-06-06
It is worth noting that in addition to the production process solutions of Taibang Bio-Blood Products, Merck has been playing an increasingly important role in the innovation and development of China's biomedicine in the decades since entering the Chinese market.
-
Has the thrombosis problem after immunization with the COVID-19 recombinant vector vaccine been overcome?
Time of Update: 2021-06-06
Scientists have discovered that poor splicing events that occur after the transcription of S protein in human cells may cause the C-terminus of the protein to be truncated (shortened), resulting in soluble S protein being released into the blood and interacting with tissues that express ACE2 receptors.
-
[One picture, one drug] Pegcetacoplan, the first complement C3 inhibitor marketed for the treatment of PNH
Time of Update: 2021-06-05
Long press the QR code to receive Pegcetacoplan (EMPAVELI®) developed by Apellis Pharmaceuticals, a C3 inhibitor, which was approved by the FDA in May 2021 for the treatment of paroxysmal nocturnal hemoglobinuria in adults [1].
-
REALISE Study: A new dosage regimen of Rucotinib in the treatment of MF patients with anemia
Time of Update: 2021-06-05
Throughout the treatment period, the hemoglobin level and platelet count remain stable, and the need for blood transfusion in patients with blood transfusion dependence is reduced without cause Baseline with anemia or anemia during treatment and delay or suspension of rucotinib treatment Study method: 10 mg bid starting dose, gradually increasing the dose REALISE study is an open-label, single-arm, phase 2 study, in Europe, Asia and North America Of the 20 centers enrolled 51 adult patients with PMF (66.
-
AAV gene therapy for hemophilia reapplies for listing!
Time of Update: 2021-06-05
The regulatory agency requires BioMarin to provide previous research data from the GENEr8-1 Phase 3 clinical trial (BMN 270-301) to evaluate the effectiveness of the drug.
BioMarin announces one-year follow-up data for the Phase 3 trial of gene therapy for hemophilia AYi Mai Meng broke the news.
-
2021 ASCO prospective | Selection of induction treatment options for newly-treated MCL patients
Time of Update: 2021-06-05
Phase II E1411 study of bendamustine combined with rituximab (BR regimen) It is explored whether the induction therapy program combined with bortezomib (BVR program) can improve the progression-free survival (PFS) of MCL patients on the basis of the research.
-
Professor Huang Huiqiang: The CSF-ctDNA 5 gene model is first proposed in the world to predict DLBCL central invasion, which has great clinical significance
Time of Update: 2021-06-05
At present, cfDNA detection, a modern molecular biology method that is clinically concerned, uses NGS technology to find information about trace gene mutations related to B/T cell lymphoma in cerebrospinal fluid, assist early diagnosis, and identify high-risk patients.
-
Chongqing Precision Biotech officially launches C-4-29 cell therapy registration clinical trial for relapsed/refractory multiple myeloma | Yimai Meng broke the news
Time of Update: 2021-06-05
Antigen receptor T lymphocyte (CAR-T) preparation (C-4-29) for the treatment of patients with relapsed/refractory multiple myeloma phase I clinical trial study kick-off meeting".
At present, the company is fully advancing the registration of clinical trials and is preparing to apply for CAR-T cell treatment of solid tumors IND.
-
The US FDA grants Legendary Biologics BCMA CAR-T priority review qualification, which is expected to be approved for listing this year | Yimai Meng broke the news
Time of Update: 2021-06-05
May 28, 2021/MedClub News/--Legendary Bio announced that the US FDA has accepted its BCMA CAR-T cell therapy ciltacabtagene autoleucel ( cilta-cel) Priority review of the Biological Agent License Application (BLA), the PDUFA date has been confirmed as November 29, 2021.
-
ASCO 2021: Summary Overview and Outlook 16 | The potential role of ctDNA in predicting colorectal cancer recurrence and overall management
Time of Update: 2021-06-04
ASCO ctDNA test to evaluate colorectal cancerThe purpose of this prospective multi-center study is to determine whether the use of ctDNA testing after multiple operations can identify high-risk relapsed patients, detect relapse earlier than standard radionuclide imaging, and evaluate adjuvant therapy.
-
JCO: Gemtuzumab Ozogamicin can improve the prognosis of children with KMT2A rearranged AML and reduce recurrence!
Time of Update: 2021-06-04
About 20% of pediatric acute myeloid leukemia (AML) cases have chromosomal reorganization involving the KMT2A gene (KMT2A-r)This study aimed to evaluate the effect of CD33-targeted drug gemtuzumab ozogamicin (GO) on the survival and prognosis of children with KMT2A-r AML enrolled in the Childhood Oncology Group Trial AAML0531 (NCT01407757).
-
New research!
Time of Update: 2021-06-04
2 variant in the serum of people with monoclonal antibodies (mabs), patients in the recovery period of new crowns, and vaccinators Antibody sensitivity.
-
What is the cause of "hematuria"?
Time of Update: 2021-06-04
Through the examination of the morphology of urine red blood cells, it can be preliminarily judged whether it is "glomerular hematuria (also called medical hematuria)" or "non-glomerular hematuria (also called surgical hematuria)", if it is the former , You need to go to the nephrology internal medicine department to further improve the relevant examinations to determine which type of kidney disease it is.
-
Document issued in one place: Gene sequencer speeds up import restrictions
Time of Update: 2021-06-03
Comparing the list of imported products released by Guangdong Province in recent years, it can be found that the 86 types of medical equipment that have been reduced this year, including gene sequencers, have released signals that the field of genetic testing is expected to accelerate the realization of import substitution.
-
Today's "Cell": The switch to burn calories has been found!
Time of Update: 2021-06-03
Researchers also used mouse models to increase the expression of GPR3 receptors on the surface of their brown fat cells through genetic modification.
The researchers designed a gene therapy that can selectively target mouse brown fat cells to increase GPR3 levels.
-
International Perspective | On the Present and Future of GVHD Prevention and Control at Home and Abroad
Time of Update: 2021-06-02
In addition to the progress made in the prevention of acute GVHD (aGVHD) and chronic GVHD (cGVHD), there are currently several Drugs can be used for the treatment of glucocorticoid resistance or advanced GVHD, and more importantly, researchers are trying to push these new therapies to the first-line treatment, rather than waiting for patients to develop glucocorticoid resistance or refractory.
-
Professor Wang Huaqing: Standardized treatment of HL and progress of new drugs|Jinling Lymphoma Forum 2021
Time of Update: 2021-06-02
In addition, the Phase 2 study of NU1608 evaluated the efficacy and safety of pembrolizumab sequential AVD (P-AVD) regimen in the first-line treatment of 30 patients with early poor prognosis and advanced cHL.
-
ASCO&EHA | Genxi Bio will announce the latest results of BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in the treatment of relapsed or refractory multiple myeloma
Time of Update: 2021-06-02
Recent popular reports from Yimaike ★ Genxi Biology announced at the AACR annual meeting the long-term follow-up data of the universal allogeneic CAR-T therapy GC027 developed based on TruUCAR for r/
-
PNH Famous Doctors Lecture 1st | Professor Fu Rong: The pathogenesis and treatment mechanism of PNH
Time of Update: 2021-06-02
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell gene mutation caused by erythrocyte membrane defects.
The mechanism of action of C5 complement inhibitors in the treatment of PNH PNH is caused by mutations in the PIG-A gene on hematopoietic stem cells.
